Welcome to our dedicated page for SL Science Holding SEC filings (Ticker: SLBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SLBT SEC filings page on Stock Titan is intended to provide access to regulatory documents associated with SL Science Holding Limited, the post-business combination holding company tied to SL BIO Ltd. and Horizon Space Acquisition II Corp. SLBT is expected to be the Nasdaq ticker symbol for this holding company if the proposed business combination is completed and listing conditions are met.
For this transaction, a registration statement on Form F-4 has been declared effective by the U.S. Securities and Exchange Commission. That document, together with the accompanying proxy statement/prospectus, describes the terms of the business combination between SL BIO Ltd., a biomedical company focused on cellular and gene therapies, and Horizon Space Acquisition II Corp., a special purpose acquisition company (SPAC). Once available under the SLBT symbol, SEC filings can include registration statements, periodic reports, and other disclosures relating to the combined company.
Stock Titan enhances these filings with AI-powered summaries that are designed to highlight key sections of lengthy documents. For example, when SLBT files annual reports on Form 10-K or foreign private issuer equivalents, quarterly reports on Form 10-Q (if applicable), or current reports on Form 8-K, the platform can surface major risk factors, business descriptions, and transaction updates in a more accessible format.
In addition, when insider transaction reports on Form 4 or other ownership-related filings become available for SLBT, this page will organize them alongside other SEC submissions. Real-time updates from the EDGAR system and AI-assisted explanations help users quickly understand the regulatory information that shapes the SLBT investment profile.
SL Science Holding Ltd discloses that CEO and chairman Ching-Dong Wang, together with SL Link Holding Ltd. and SL Link Co., Ltd., beneficially owns 333,832,129 ordinary shares, representing approximately 59.53% of the company. This stake arose from the business combination between SL BIO Ltd. and Horizon Space Acquisition II Corp. completed on June 12, 2026.
The 333,832,129 ordinary shares include 329,286,823 shares held by SL Link Holding Ltd. and 4,545,306 shares held by SL Link Co., Ltd. The percentages are based on about 560,759,757 ordinary shares issued and outstanding, excluding 260,000 ordinary shares issuable upon conversion of 780,000 preferred shares.
SL Science Holding Ltd director and Chief Executive Officer Wang Ching-Dong filed an initial ownership report showing beneficial ownership of 333,832,129 Ordinary Shares of the company.
These holdings are owned indirectly through SL Link Holding Ltd. and SL Link Co., Ltd., over which Mr. Wang has voting and dispositive power.
SL Science Holding Limited has completed its business combination with Horizon Space Acquisition II Corp., becoming the Nasdaq-listed holding company for SL Bio and focusing on advanced cell and gene therapies. The company is still pre-revenue in therapeutics, with all lead programs in pre-clinical development and no FDA INDs or approvals.
SL Bio reported 2025 net revenue of $2.2 million, down from $3.4 million in 2024, mainly from exosome and plant-extract cosmetics in Taiwan, and a net loss of $3.8 million. Pro forma cash was $9.0 million and total capitalization $9.7 million as of December 31, 2025.
The company’s pipeline centers on CD-19 Armed-T therapy for blood cancers and gamma delta T cell therapies for pancreatic cancer and glioblastoma, supported by long-term licenses from CytoArm and JY BioMed that include up to $4.1 million and $37 million in milestone payments, plus sales-based royalties. Significant additional nonclinical work and FDA interactions are required before clinical trials can begin.
SL Science Holding Ltd director Xu Qian has filed an initial Form 3, reporting direct ownership of 20,000 Ordinary Shares of SL Science Holding Ltd. This filing establishes Xu Qian’s reported equity position as an insider and does not disclose any recent share purchases or sales.
SL Science Holding Ltd filed an initial Form 3 for Johnson Shun-Pong Lau, who serves as Vice President of Finance. The filing reports his status as an officer but does not list any specific share holdings or transactions in company securities.
SL Science Holding Ltd director and Chief Technology Officer Ethan Shen, PhD has filed an initial Form 3 ownership report as an insider of the company. The filing does not report any share purchases, sales, option exercises, or other equity transactions at this time.
SL Science Holding Ltd filed an initial Form 3 for director Liu Mingche. This filing serves as the first statement of beneficial ownership for this insider and establishes a baseline record of their reporting status with no transactions disclosed in this document.
SL Science Holding Ltd director Chen Kwo-Liang has filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The filing lists his status as a director of the company but does not report any current holdings or recent transactions in SLBT securities.
SL Science Holding Ltd director General John Conrad filed an initial ownership report on Form 3. This filing identifies him as a director and reporting person for SLBT but shows no reported stock or derivative holdings and no buy, sell, or other insider transactions.
SL Science Holding Ltd filed an initial Form 3 for Chief Financial Officer Leung Lok Sang. This filing reports no insider transactions or derivative positions, with all buy, sell, exercise, and other transaction counts shown as zero in the summary data.